Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

Figure 2

Effects of Selectikine treatment on peripheral CD4+and CD8+T-cells. (A) Absolute counts (cells/mm3) and frequencies (%) of CD3+CD4+ and CD3+CD8+ T-cells (gated on lymphocytes using FSC/SSC parameters) on days 1 and 8 during the first and second treatment cycles. Graphs show the individual values of 39 patients treated with 0.075 to 0.9 mg/kg Selectikine alone. Bars represent geometric mean values, with 95% CI. (B) CD4+/CD8+ ratios on days 1 and 8 during the first and second treatment cycles. Box-and-whiskers graphs show geometric mean with 95% CI. (C) Serum concentrations (ng/mL) of soluble interleukin-2 receptor on days 1 and 3 during the first and second treatment cycle. The box and whisker graph shows geometric mean values per dose-group. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.005.

Back to article page